EFFICACY AND SAFETY OF HSK39297, A ONCE-DAILY ORAL CFB INHIBITOR, IN PATIENTS WITH PRIMARY IMMUNOGLOBULIN A NEPHROPATHY: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II TRIAL

 

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

 

 

Certificate Background

   

Presented the abstract " "
(Abstract co-author(s):  )

 

 

  Back
E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center. 

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

​E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.​

E-Poster Format Requirements
  • PDF file
  • Layout: Portrait (vertical orientation)
  • One page only (Dim A4: 210 x 297mm or PPT)
  • E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
  • File Size: Maximum file size is 2 Megabytes (2 MB)
  • No hyperlinks, animated images, animations, and slide transitions
  • Language: English
  • Include your abstract number
  • E-posters can include QR codes, tables and photos
https://storage.unitedwebnetwork.com/files/1099/ece2adedd853f5e4a61ae99875fcdb1c.pdf
EFFICACY AND SAFETY OF HSK39297, A ONCE-DAILY ORAL CFB INHIBITOR, IN PATIENTS WITH PRIMARY IMMUNOGLOBULIN A NEPHROPATHY: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II TRIAL

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

  • The title will not be accepted if it exceeds 25 words.
  • Type in CAPITAL LETTERS.
  • Lowercase may be used for abbreviations only, for example, mRNA.
Jicheng
Lv
Jicheng Lv wangchaoyf@haisco.com Peking University First Hospital renal division, department of medicine Beijing China *
Jiang Liu wangchaoyf@haisco.com Ningbo Medical Treatment Center Lihuili Hospital renal division, department of medicine Ningbo China -
Huaying Pei wangchaoyf@haisco.com The Second Hospital of Hebei Medical University renal division, department of medicine Shijiazhuang China -
Yan Hao wangchaoyf@haisco.com Zigong First People's Hospital renal division, department of medicine Zigong China -
Yanlin Li wangchaoyf@haisco.com Zhongshan Municipal Hospital of Traditional Chinese Medicine renal division, department of medicine Zhongshan China -
Rui Yan wangchaoyf@haisco.com The Affiliated Hospital of Guizhou Medical University renal division, department of medicine Guiyang China -
Hui Xu wangchaoyf@haisco.com Xiangya Hospital of Central South University renal division, department of medicine Changsha China -
Xuanyi Du wangchaoyf@haisco.com The Second Affiliated Hospital of Harbin Medical University renal division, department of medicine Harbin China -
Bin Liu wangchaoyf@haisco.com Wuxi People's Hospital renal division, department of medicine Wuxi China -
Hongqian Guo wangchaoyf@haisco.com Nanjing Drum Tower Hospital renal division, department of medicine Nanjing China -
Yaling Bai wangchaoyf@haisco.com The Fourth Hospital of Hebei Medical University renal division, department of medicine Shijiazhuang China -
Feng Huang wangchaoyf@haisco.com Linyi People's Hospital renal division, department of medicine Linyi China -
Fangqiong Li lifangq@haisco.com Haisco Pharmaceutical Group Co. Ltd. Clinical Medicine Department Chengdu China -
Hong Zhang hongzh@bjmu.edu.cn Peking University First Hospital renal division, department of medicine Beijing China -
-